APG Asset Management US Inc. Purchases 83,554 Shares of Pfizer Inc. (NYSE:PFE)

APG Asset Management US Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 249.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 117,103 shares of the biopharmaceutical company's stock after acquiring an additional 83,554 shares during the quarter. APG Asset Management US Inc.'s holdings in Pfizer were worth $3,107,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Pfizer by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after buying an additional 2,923,537 shares during the period. Norges Bank purchased a new stake in shares of Pfizer in the fourth quarter worth about $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of analysts recently weighed in on PFE shares. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.07.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.06% of the company's stock.

Pfizer Price Performance

NYSE PFE traded up $0.30 on Friday, reaching $21.89. 55,013,451 shares of the company's stock traded hands, compared to its average volume of 40,232,439. The stock has a market cap of $124.14 billion, a PE ratio of 15.52, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a 50-day simple moving average of $25.25 and a 200 day simple moving average of $26.38.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.